Breast Cancer Clinical Trials in Boston

Showing 141-160 of 509 trials

The COMPASSION Study

NCT06507930

The aim of this research study is to better understand the in-home hospice experience for participants, caregivers, hospice nurses, and oncology providers by conducting telehealth check-ins between participants and caregivers and oncology care teams.

Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+1 more

Dana-Farber Cancer Institute200 participantsStarted Sep 2024

Boston, Massachusetts, United States

Active Not RecruitingPhase 2< 1 mile

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

NCT04837209

This research study is looking to see whether the combination of Dostarlimab and Niraparib plus Radiation Therapy (RT) is safe and effective in participants with metastatic triple negative breast cancer. The names of the study treatment involved in this study are: * Dostarlimab * Niraparib * Radiation Therapy (RT), which is given per standard of care.

Breast CancerTriple Negative Breast Cancer

Massachusetts General Hospital32 participantsStarted Jul 2021

Washington D.C., District of Columbia, United States • Boston, Massachusetts, United States • Durham, North Carolina, United States +1 more locations

Active Not RecruitingPhase 1< 1 mile

PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer

NCT03362060

This research study is studying immunotherapy as a possible treatment for metastatic Triple Negative Breast Cancer (TNBC) in participants who are HLA-A2+. The drugs involved in this study are: * PVX-410 * Pembrolizumab * Hiltonol * Montanide

Triple Negative Breast CancerMetastatic Breast Cancer

Massachusetts General Hospital20 participantsStarted Dec 2017

Boston, Massachusetts, United States • Boston, Massachusetts, United States • Boston, Massachusetts, United States

The COMPASSION Study

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer

Breast Cancer Trials in Other Cities

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

MarginProbe 2.0 Data Collection Protocol

Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

A Study of ADRX-0706 in Select Advanced Solid Tumors

Other Conditions in Boston